Which Patients Does the SPRINT Study Not Apply To and What Are the Appropriate Blood Pressure Goals in These Populations?

Journal of Clinical Hypertension

Volumn 18, Issue 5, 2016, Pages 477-478

  Cohen, Debbie L ^a   Townsend, Raymond R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LACUNAR STROKE; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; NATIONAL HEALTH ORGANIZATION; ORGANIZATION AND MANAGEMENT; PATIENT CARE PLANNING; PHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STANDARDS; SYSTOLE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PATIENT CARE PLANNING; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SYSTOLE; UNITED STATES;

EID: 84953304144     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12766     Document Type: Article

References (10)

1. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532-546.
2. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116.
3. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
4. Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2255-2266.
5. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension. 1997;1:428-435.
6. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-946.
7. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
8. Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int. 2013;83:377-383.
9. Weir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015;26:1248-1260.
10. Pearce LA, McClure LA, Anderson DC, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol. 2014;13:1177-1185.